Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Massimo Lemoli

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Leukemia & Lymphoma|March 19, 2020
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patientsFabio Guolo, Paola Minetto, Marino Clavio, et al.
Leukemia Research|September 27, 2019
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemiaRiccardo Marcolin, Fabio Guolo, Paola Minetto, et al.
Hematological Oncology|December 5, 2024
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual DiseaseCarola Riva, Paola Minetto, Maria Chies, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 25, 2018
Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission TomographyCarlo Marani, Anna Maria Raiola, Silvia Morbelli, et al.
Haematologica|May 15, 2003
High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experiencePier Luigi Zinzani, Monica Tani, Annalisa Gabriele, et al.
Cancers|December 30, 2020
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of <i>FLT3</i>-ITD in <i>NPM1</i> Mutated AML, Irrespectively of <i>FLT3</i>-ITD Allelic BurdenPaola Minetto, Anna Candoni, Fabio Guolo, et al.
Annals of Hematology|July 4, 2014
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemiaEnrico De Astis, Marino Clavio, Anna Maria Raiola, et al.
Leukemia & Lymphoma|April 23, 2004
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experiencePier Luigi Zinzani, Monica Tani, Annalisa Gabriele, et al.
The Oncologist|March 10, 2026
Long-Term Health-Related Quality of Life and Lifestyle Behavior of Patients with Acute Myeloid LeukemiaFabio Efficace, Laura Cannella, Xavier Thomas, et al.
European Journal of Haematology|July 23, 2021
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantationFabio Guolo, Carmen Di Grazia, Paola Minetto, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Leukemia & Lymphoma|March 19, 2020
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patientsFabio Guolo, Paola Minetto, Marino Clavio, et al.
Leukemia Research|September 27, 2019
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemiaRiccardo Marcolin, Fabio Guolo, Paola Minetto, et al.
Hematological Oncology|December 5, 2024
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual DiseaseCarola Riva, Paola Minetto, Maria Chies, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 25, 2018
Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission TomographyCarlo Marani, Anna Maria Raiola, Silvia Morbelli, et al.
Haematologica|May 15, 2003
High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experiencePier Luigi Zinzani, Monica Tani, Annalisa Gabriele, et al.
Cancers|December 30, 2020
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of <i>FLT3</i>-ITD in <i>NPM1</i> Mutated AML, Irrespectively of <i>FLT3</i>-ITD Allelic BurdenPaola Minetto, Anna Candoni, Fabio Guolo, et al.
Annals of Hematology|July 4, 2014
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemiaEnrico De Astis, Marino Clavio, Anna Maria Raiola, et al.
Leukemia & Lymphoma|April 23, 2004
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experiencePier Luigi Zinzani, Monica Tani, Annalisa Gabriele, et al.
The Oncologist|March 10, 2026
Long-Term Health-Related Quality of Life and Lifestyle Behavior of Patients with Acute Myeloid LeukemiaFabio Efficace, Laura Cannella, Xavier Thomas, et al.
European Journal of Haematology|July 23, 2021
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantationFabio Guolo, Carmen Di Grazia, Paola Minetto, et al.
Pageof 5